Kaken Pharmaceutical Co Ltd 2024 Integrated Report
The report presents FY2023 consolidated sales of ¥72.0 billion, a Sustainability Committee and Board oversight structure, and environmental targets including a 51% emissions reduction by FY2030 and net zero by 2050. It also reports 1,135 consolidated employees, 4,167 training hours and a 65.6% total employee engagement positive response rate.
Company: Kaken Pharmaceutical Co Ltd
Sector: Manufacturing
Country: Japan
Year: 2024
Type: Integrated Report
Pages: 51
Back to company
Kaken Pharmaceutical Co Ltd
Corporate Report
The report presents FY2023 consolidated sales of ¥72.0 billion, a Sustainability Committee and Board oversight structure, and environmental targets including a 51% emissions reduction by FY2030 and net zero by 2050. It also reports 1,135 consolidated employees, 4,167 training hours and a 65.6% total employee engagement positive response rate.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Apr 1, 2023 - Mar 31, 2024
Fiscal Year
2023
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Renewable Energy
Water Consumption
Total Waste
Women on Board
Women in Management
Net Zero Target
Employees